Age-related macular degeneration or AMD is the leading cause of adult blindness in developed countries and affects nearly 1 in 8 adults over the age of 60. AMD is a chronic, progressive disease that attacks the macula, a part of the retina that allows us to see objects located straight ahead of us. The macula is responsible for your central vision, which allows you to do things like recognize faces, read, watch TV, and drive.
Stages of Age-Related Macular Degeneration
As a progressive disease, AMD reveals itself in stages.
• Subclinical AMD is the earliest detectable stage of age-related macular degeneration. The first warning sign comes in the form of trouble seeing at night. Many people blame poor night vision (caused by impaired “dark adaptation”) on the normal aging process and don’t report the symptom to their doctor. Don’t make that mistake. If you begin having difficulty driving at night, reading in dim light or adjusting to seeing in the dark, tell your eye care professional. Identifying AMD at this point is critical to proactively managing AMD
.• Early to Intermediate AMD Before, we learned that dark adaptation is the first symptom of AMD, eye care professionals relied on identifying the disease during the early or intermediate stages. At this point, your doctor may see drusen—yellow deposits of fatty protein under your retina—which is an indicator of AMD.
• Advanced AMD: During late-stage AMD, people start to notice central vision blurriness. The transition from early-stage to late-stage AMD happens rapidly. If left untreated, it can lead to legal blindness in as little as six months. While treatment options can slow the progression of late AMD, nothing can reverse the damage already done.
AMD Symptoms and Risk Factors
The earliest symptom of AMD is impaired dark adaptation, which may cause difficulty seeing or driving at night. As the disease progresses, symptoms may include distortion of straight lines or dark and blurry central vision.
The primary risk factors for AMD include:
• Age 50 or older
• Family history of AMD
• Caucasian (white)
• Smoker or past smoker
• Heart disease, high blood pressure or high cholesterol
Age is the biggest risk factor. In fact, 1 in 8 adults over the age of 60 have age-related macular degeneration (AMD). If you are experiencing a symptom of AMD or have multiple risk factors, ask your doctor to test your eyes with the AdaptDx®.
• It is projected that the overall prevalence of the AMD will be 196 million in 2020 and 288 million in20401.
• As many as 11 million people in the U.S. have clinical AMD; this number is expected to double by20501.
• Up to 78% of AMD patients have substantial, irreversible vision loss at first treatment, including 37%who are legally blind in at least one eye2,3.
• Currently, there is no cure for AMD but progression of the disease can be slowed or halted with lifestyle modifications, protective eyewear, and nutritional supplements. Timely diagnosis is therefore key.
• Wet AMD (choroidal neovascularization or CNV) may be treated with injections, which can slow or halt disease progression and vision loss, but not reverse it.
What happens if AMD is detected?
If you are diagnosed with AMD, you and your doctor have valuable time to develop a plan to delay further symptoms. Proactive steps to delay or prevent vision loss:
• Lifestyle changes, such as improved diet and exercise and quitting smoking
• Eye health supplements
• Blue light protection
• UVA and UVB protection
We will also want to monitor your vision regularly. If needed, you’ll be able to begin additional treatment as soon as late-stage AMD is detected.
Identifying AMD at a subclinical stage allows patients to work with their eye doctor to take action before significant vision loss has occurred. Putting a care plan in place at the earliest possible time will preserve as much vision as possible over a longer duration. Our practice is excited to offer this revolutionary dark adaptation test to our patients, using the theAdaptDx Pro, which detects AMD in its earliest stages. This simple, non-invasive test measures the Rod intercept™(RI™), which is the time in minutes it takes the patient’s eye to adapt from bright light to darkness (dark adaptation).
The AdaptDx Pro test lasts less than 15 minutes and can easily fit into a comprehensive eye examination. This test of retinal function complements the structural imaging and photography of the retina for a more robust evaluation of retinal health. Once AMD is detected, this device can help monitor the progression of the disease.
About AdaptDx Pro
Based on the science of dark adaptation, MacuLogix’s AdaptDx Pro provides a clear, objective measurement of retinal function that is 90% sensitive and 90% specific to the presence of AMD. A single number, the Rod Intercept (RI), can be useful in diagnosing AMD at the subclinical stage – at least 3 years before drusen are visible – when a course of action may help delay or prevent blindness caused by AMD. The AdaptDx Pro is assembled in the USA by MacuLogix, Inc. Please ask our optometrist for more information